Approaches for the rapid identification of drug metabolites in early clinical studies

Bioanalysis

Volumn 3, Issue 2, 2011, Pages 197-213

  Dear, Gordon J ^a   Beaumont, Claire ^a   Roberts, Andrew ^a   Squillaci, Bianca ^a   Thomas, Steve ^a   Nash, Mike ^a   Fraser, Donna ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE;

ANALYTIC METHOD; CLUSTER ANALYSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

AUTOMATIC DATA PROCESSING; BODY FLUIDS; CHEMISTRY TECHNIQUES, ANALYTICAL; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY;

EID: 79951929075     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.186     Document Type: Review

References (131)

1. Baillie TA, Cayen MN, Fouda H et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196 (2002).
2. Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg RE. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190, 91-92 (2003).
3. Baillie TA, Cayen MN, Fouda H et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190, 93-94 (2003).
4. Smith DA, Obach RS. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33, 1409-1417 (2005). (Pubitemid 41323986)
5. Smith DA, Obach RS. Metabolites and safety: what are the concerns and how should we address them? Chem. Res. Toxicol. 19, 1570-1579 (2006). (Pubitemid 44975120)
6. Davis-Bruno KL, Atrakchi A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 1561-1563 (2006). (Pubitemid 44975118)
7. Humphreys WG, Unger SE. Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem. Res. Toxicol. 19, 1564-1569 (2006). (Pubitemid 44975119)
8. Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and performed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152 (2006). (Pubitemid 44780764)
9. Leclercq L, Cuyckens F, Mannens GSJ, de Vries R, Timmerman P, Evans DC Which human metabolites have we MIST? Retrospective ana lysis, practical aspects, and perspectives for metabolite identifcation and quantifcation in pharmaceutical development. Chem. Res. Toxicol. 22, 280-293 (2009).
10. Luffer-Atlas D. Unique/major human metabolites: why, how and when to test for safety in animals. Drug Metab. Rev. 40, 447-463 (2008). (Pubitemid 352019965)
11. Nedderman A. Metabolites in safety testing: metabolite identifcation strategies in discovery and development. Biopharm. Drug Dispos. 30, 153-162 (2009).
12. Zhu M, Zhang D, Zhang H, Chyi Shyu W. Integrated strategies for assessment of metabolite exposure in human during drug development: analytical challenges and clinical development considerations. Biopharm. Drug Dispos. 30, 163-184 (2009).
13. Walker D, Brady J, Dalvie D et al. A holistic strategy for characterising the safety of metabolites through drug discovery and development. Chem. Res. Toxicol. 22, 1653-1662 (2009).
14. Federick CB, Obach RS. Metabolites in safety testing: 'MIST' for the clinical pharmacologist. Clin. Pharm. Therap. 87(3), 345-350 (2010).
15. Nedderman NR, Wright P. Looking back through the MIST: a perspective of evolving strategies and key focus for metabolite safety Bioana lysis 2(7) 1235-1248 (2010).
16. Atrakchi AH. Interpretation and considerations on the safety evaluation of human drug metabolites. Chem. Res. Toxicol. 22, 1217-1220 (2009).
17. Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm. Drug Dispos. 30, 185-203 (2009).
18. Hop CE, Wang Z, Chen Q, Kwei G. Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J. Pharm. Sci. 87, 901-903 (1998). (Pubitemid 28319423)
19. Tarning J, Bergqvist Y, Day NP et al. Characterisation of human urinary metabolites of the antimalarial piperaquine. Drug Met. Dispos. 34(12) 2011-19 (2006). (Pubitemid 44837762)
20. Yang W, Wang Y, Zhou Q, Tang H. Analysis of human urine metabolites using SPE and NMR spectroscopy. Sci. China Ser. B-Chem. 51(3) 218-225 (2008). (Pubitemid 351652540)
21. Tevell A, Bondesson U, Torneke K, Hedeland M. Identifcation of some new clemastine metabolites in dog, horse and human urine with liquid chromatography-tandem mass spectrometry Rapid Commun. Mass Spectrom. 18, 2267-2272 (2004). (Pubitemid 39297364)
22. Souverain S, Rudaz S, Veuthey JL. Restricted access materials and large particle supports for on-line sample preparation: an attractive approach for biological fuids ana lysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 801, 141-156 (2004). (Pubitemid 38130063)
23. Walles M, Mullet WM, Levsen K, Borlak J, Wunsch G, Pawliszyn J. Verapamil drug metabolism studies by automated in-tube solid phase microextraction. J. Pharm. Biomed. Anal. 30, 307-319 (2002). (Pubitemid 35013497)
24. Gmeiner G, Gartner P, Krassnig C, Tausch H. Identifcation of various urinary metabolites of fuorene using derivatisation solid-phase microextraction. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 766, 209-218 (2002). (Pubitemid 34142352)
25. Nielsen S, Freese R, Cornett C, Dragsted LO. Identifcation and quantifcation of favonoids in human urine samples by column-switching liquid chromatography coupled to atmospheric pressure chemical ionisation mass spectrometry Anal. Chem. 72, 1503-1509 (2000). (Pubitemid 30185738)
26. Katagi M, Nishikawa M, Tatsuno M, Miki A, Tsuchihashi H. Column-switching high-performance liquid chromatography-electrospray ionisation mass spectrometry for identifcation of heroin metabolites in human urine. J. Chromatogr. B Biomed. Sci. Appl. 751, 177-185 (2001). (Pubitemid 32146326)
27. Plumb RS, Dear GJ, Ayrton J, Sweatman BC, Ismail IM. The use of preparative HPLC with tandem mass spectrometric directed fraction collection for the isolation and characterization of drug metabolites in urine by NMR spectrometry and LC-MS. Rapid Commun. Mass Spec. 13, 845-854 (1999).
28. Dear GJ, Ismail IM, Mutch PJ, Davies LH, Plumb R, Sweatman BC. Urinary metabolites of a novel non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identifcation of fuorine NIH shift metabolites using NMR and tandem MS. Xenobiotica 30, 407-426 (2000). (Pubitemid 30251249)
29. Cui L, Qiu F, Yao X. Isolation and identifcation of seven glucuronide conjugates of andrographolide in human urine. Drug Met. Dispos. 33(4) 555-62 (2005). (Pubitemid 40393199)
30. Dear GJ, Roberts AD, Beaumont C, North SE. Evaluation of preparative high performance liquid chromatography and cryoprobe-nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 876, 182-190 (2008).
31. Guth O, Krewer D, Freudenberg B, Paulitz C, Hauser M, Ilg K. Automated modular preparative HPLC-MS purifcation laboratory with enhanced effciency J. Comb. Chem. 10, 875-882 (2008).
32. Glauser G, Guillarne D, Grata E et al. Optimized liquid chromatography-mass spectrometry approach for the isolation of minor stress biomarkers in plant extracts and their identifcation by capillary nuclear magnetic resonance. J. Chromatogr. A 1180, 90-98 (2008).
33. Dear GJ, Ayrton J, Plumb R, Sweatman BC, Ismail IM. Tandem mass spectrometry linked fraction collection for the isolation of drug metabolites from biological matrices. Rapid Commun. Mass Spec. 13, 886-894 (1999). (Pubitemid 29235649)
34. Ruan Q, Peterman S, Szewc MA, Ma L, Cui D, Griffth-Humphreys W, Zhu M. An integrated method for metabolite detection and identifcation using a linear ion trap/Orbitrap mass spectrometer and multiple data processing techniques: application to indavir metabolite detection. J. Mass Spectrom. 43, 251-261 (2008). (Pubitemid 351303446)
35. Lim H, Chen J, Sensenhauser C, Cook K, Subrahmanyam V. Metabolite identifcation by data-dependent accurate mass spectrometric ana lysis at resolving power of 60,000 in external calibration mode using an LTQ/Orbitrap. Rapid Commun. Mass Spectrom. 21, 1821-1832 (2007). (Pubitemid 46953542)
36. Ramanathan R, McKenzie DL, Tugnait M, Siebenaler K. Application of semi-automated metabolite identifcation software in the drug discovery process for rapid identifcation of metabolites and the cytochrome P450 enzymes responsible for their formation. J. Pharm. Biomed. Anal. 28, 945-951 (2002). (Pubitemid 34564537)
37. Liu DQ, Hop CE. Strategies for characterization of drug metabolites using liquid chromatography-tandem mass spectrometry in conjunction with chemical derivatization and on-line H/D exchange approaches. J. Pharm. Bio. Anal. 37, 1-18 (2005). (Pubitemid 40138711)
38. Prakash C, Soliman V. Metabolism and excretion of a novel anti-anxiety drug candidate CP-93,393, in long evans rats-differentiation of regioisomeric glucuronides by LC-MS/MS. Drug Metab. Dispos. 25, 1288-1297 (1997). (Pubitemid 27490674)
39. Hakala KS, Kostiainen R, Ketola RA. Feasibility of different mass spectrometric techniques and programs for automated metabolite profling of tramadol in human urine. Rapid Commun. Mass Spectrom. 20, 2081-2090 (2006). (Pubitemid 44049033)
40. Cuyckens F, Hurkmans R, Castro-Perez JM, Leclercq L, Mortishire-Smith RJ. Extracting metabolite ions out of a matrix background by combined mass defect, neutral loss and isotope fltration. Rapid Commun. Mass Spectrom. 23, 327-332 (2009).
41. 15N). J. Clin. Pharmacol. 33(3) 246-52 (1993).
42. Ismail IM, Andrew PD, Cholerton J et al. Characterization of the metabolites of alosetron in experimental animals and human. Xenobiotica 35, 131-154 (2005). (Pubitemid 40769765)
43. Leal M, Hayes MJ, Powell ML. The metabolism of CGS 15873 in man using stable isotope pattern recognition techniques. Biopharm. Drug. Dispos. 13, 617-628 (1992).
44. Jacob P 3rd, Benowitz NL, Shulgin AT. Recent studies of nicotine metabolism in humans. Pharmacol. Biochem. Behav. 30, 249-253 (1988). (Pubitemid 19268818)
45. Zhu P, Tong W, Alton K, Chowdhury S. An accurate-mass-based spectral-averaging isotope-pattern-fltering algorithm for extraction of drug metabolites possessing a distinct isotope pattern from LC-MS data. Anal. Chem. 81, 5910-5917 (2009).
46. Gammelgaard B, Jensen BP. Application of inductively coupled plasma mass spectrometry in drug metabolism studies. J. Anal. At. Spectrom. 22, 235-249 (2007). (Pubitemid 46353905)
47. Gammelgaard B, Hansen HR, Stürup S, Møller C. The use of inductively coupled mass spectrometry as a detector in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 4, 1187-1207 (2008).
48. Cuycken F, Balcaen LIL, De Wolf K et al. Use of the bromine isotope ratio in HPLC-ICP-MS and HPLC-ESI-MS ana lysis of a new drug in development. Anal. Bioanal. Chem. 390, 1717-1729 (2008).
49. 19F-NMR spectroscopy, HPLC-MS/MS, HPLC-ICP-MS and HPLC-NMR. Xenobiotica 36, 59-77 (2006). (Pubitemid 43315846)
50. Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 4, 1021-1033 (2008).
51. Dear GJ, James AD, Sarda S. Ultra-performance liquid chromatography coupled to linear ion trap mass spectrometry for the identifcation of drug metabolites in biological samples. Rapid Commun. Mass Spectrom. 20, 1351-1360 (2006).
52. Zhang H, Zhu M, Ray KL, Ma L, Zhang D. Mass defect profles of biological matrices and the general applicability of mass defect fltering for metabolite detection. Rapid Commun. Mass Spectrom. 22, 2082-2088 (2008). (Pubitemid 351956694)
53. Zhu M, Ma L, Zhang D et al. Detection and characterization of metabolites in biological matrices using mass defect fltering of liquid chromatography-high resolution mass spectrometry data. Drug Met. Dispos. 34, 1722-1733 (2006). (Pubitemid 44427475)
54. Zhang D, Cheng PT, Zhang H. Mass defect fltering on high resolution LC-MS data as a methodology for detecting metabolites with unpredictable structures: identifcation of oxazole-ring opened metabolites of muraglitazar. Drug Metab. Lett. 1, 287-292 (2007).
55. e with mass defect fltering for in vitro and in vivo metabolite identifcation. Rapid Commun. Mass Spectrom. 21, 1485-1496 (2007). (Pubitemid 46761970)
56. Huang Y, Liu S, Miao S, Jeanville PM. Using multiple mass defect flters and higher energy collisional dissociation on an LTQ Orbitrap XL for fast, sensitive and accurate metabolite ID. Thermo Fisher Scientifc Application Note 417, 1 May 2008.
57. Tiller PR, Yu S, Bateman KP, Castro-Perez J, Mcintosh IS, Kuo Y, Baillie TA. Fractional mass fltering as a means to assess circulating metabolites in early human clinical studies. Rapid Commun. Mass Spectrom. 22, 3510-3516 (2008).
58. Mortishire-Smith RJ, Castro-Perez JM, Yu K et al. Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect flters. Rapid Commun. Mass Spectrom. 23, 939-948 (2009).
59. Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN, Dear GJ. Use of liquid chromatography-time-of-fight mass spectrometry and multivariate statistical ana lysis shows promise for the detection of drug metabolites in biological fuids. Rapid Commun. Mass Spectrom. 17, 2632-2638 (2003). (Pubitemid 37498776)
60. Schneider RP, Zhang H, Mu L, Kalgutkar AS, Bonner R. Utility of multivariate ana lysis in support of in vitro metabolite identifcation studies: retrospective ana lysis using the antidepressant drug nefazodone. Xenobiotica 40, 262-274 (2010).
61. Li F, Patterson AD, Höfer CC, Krausz KW, Gonzalez FJ, Idle JR. Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. Biochem. Pharmacol. 80, 1063-1074 (2010).
62. Oliveira EJ, Watson DG. Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed. Chromatogr. 14, 351-372 (2000).
63. Liu DQ, Xia Y-Q, Bakhtiar R. Use of a liquid chromatography-ion trap mass spectrometry/triple quadrupole mass spectrometry system for metabolite identifcation. Rapid Commun. Mass Spectrom. 16, 1330-1336 (2002). (Pubitemid 34717259)
64. Brooks RT, Sternglanz PD. Titanometric determination of the N-oxide group in pyridine-N-oxide and related compounds. Anal. Chem. 31, 561-565 (1959).
65. Seaton QF, Lawley CW, Akers HA. The reduction of aliphatic and aromatic N-oxides to the corresponding amines with titanium (III). Anal. Biochem. 138(1), 238-41 (1984).
66. Legault RR, Groves K. Determination of sulfoxides. Anal. Chem. 29, 1495-1496 (1957).
67. Kulanthaivel P, Barbuch RJ, Davidson RS et al. Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab. Dispos. 32, 966-972 (2004). (Pubitemid 39096057)
68. Liu D, Hop CE, Beconi MG, Mao A, Chiu SH. Use of on-line hydrogen/deuterium exchange to facilitate metabolite identification. Rapid Commun. Mass Spectrom. 15, 1832-1839 (2001). (Pubitemid 32927757)
69. Ohashi N, Furuuchi S, Yoshikawa M. Usefulness of the hydrogen-deuterium exchange method in the study of drug metabolism using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 18, 325-334 (1998). (Pubitemid 28529437)
70. Wolff JC, Laures AM. 'On the fly' hydrogen/deuterium exchange liquid chromatography-mass spectrometry using a dual-sprayer atmospheric ionisation source. Rapid Commun. Mass Spectrom. 20, 3769-3779 (2006). (Pubitemid 44935331)
71. Blau K, Halket J. Chapter 2. In: Handbook of Derivatives for Chromatography (2nd Edition). John Wiley & Sons, Inc., USA (1993).
72. Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C. Metabolism, pharmacokinetics and excretion of a highly selective N-methyl-d-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolisers. Drug Metab. Dispos. 31, 76-87 (2003). (Pubitemid 36735261)
73. Neirinckx E, Vervaet C, De Boever S et al. Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. Res. Vet. Science 89, 113-119 (2010).
74. Álvarez-Sánchez B, Priego-Capote F, Luque de Castro MD. Ultrasound-enhanced enzymatic hydrolysis of conjugated female steroids as pretreatment for their analysis by LC-MS/MS in urine. Analyst 134, 1416-1422 (2009).
75. Mueller M, Kolbrich-Spargo EA, Peters FT, Huestis MA, Ricaurte GA, Maurer HH. Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA). Anal. Bioanal. Chem. 393, 1607-17 (2009).
76. Webb AG. Advances in probe design for protein NMR. In: Annual Reports on NMR Spectroscopy. (Ed.). Academic Press, London, UK 58, 1-50 (2006). (Pubitemid 43580978)
77. Dalisay D, Molinski T. NMR quantification of natural products at the nano-mole scale. J. Nat. Prod. 72(4) 739-44 (2009).
78. Olson D, Norcross J, O'Neil M et al. Microflow NMR: concepts and capabilities. Anal. Chem. 76, 2966-2974 (2004). (Pubitemid 38657726)
79. Lewis R, Bernstein M, Duncan S, Sleigh C. A comparison of capillary-scale LC-NMR with alternative techniques: spectroscopic and practical considerations. Magn. Reson. Chem. 43, 783-789 (2005). (Pubitemid 41133761)
80. Triebe R, Nast R, Marek D, Withers R, Baselgia L, Haberli M, Gerfin T. A user friendly system for the routine application of cryogenic NMR probes: technology and resultsPresented at: 40thExperimental Nuclear Magnetic Resonance Conference. Orlando, FL, USA, 28 February-5 March 1999.
81. Kovacs H, Moskau D, Spraul M. Cryogenically cooled probes-a leap in NMR technology. Prog. Nucl. Magn. Reson. Spectrosc. 46, 131-155 (2005). (Pubitemid 40749327)
82. Chen J, Zhang JW, Yang L, Li W. Structure elucidation of major metabolites from medroxyprogesterone acetate by p450. Chem. Pharm. Bull. 57, 835-839 (2009).
83. Bhattacharya A. Chemistry: breaking the billion-hertz barrier. Nature 463, 605-606 (2010).
84. Yanagisawa Y, Nakagome H, Tennmei K et al. Operation of a 500 MHz high temperature superconducting NMR: towards an NMR spectrometer operating beyond 1 GHz. J. Mag. Res. 203, 274-282 (2010).
85. Nakamura T, Itoh Y, Yoshikawa M, Oka T, Uzawa J. Development of a superconducting magnet for nuclear magnetic resonance using bulk high-temperature superconducting materials. C. Mag. Res. 31B, 65-70 (2007).
86. Walker G, O'Connell T. Comparison of LC-NMR and conventional NMR for structure elucidation in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 4(10) 1295-305 (2008).
87. Pontoizeau C, Hermann T, Toulhoat P, Elena-Hermann B, Emsley L. Targeted projection NMR spectroscopy for unambiguous metabolic profiling of complex mixtures. Magn. Reson. Chem. 48, 727-733 (2010).
88. Watt AP, Mortishire-Smith RJ, Gerhard U, Thomas SR. Metabolite identification in drug discovery. Curr. Opin. Drug Discov. Devel. 6(1) 57-65 (2003). (Pubitemid 36206940)
89. Rossi P, Swapna GV, Huang YJ et al. A microscale protein NMR sample screening pipeline. J. Biomol. NMR 46, 11-22 (2010).
90. Spraul M, Hofman M, Wilson I, Lenz E, Nicholson J, Lindon J. Coupling of HPLC with 19F and 1H NMR spectroscopy to investigate the human urinary excretion of flurbiprofen metabolites. J. Pharm. Biomed. Anal. 11(10) 1009-15 (1993). (Pubitemid 23340989)
91. Desmoulin F, Gilard V, Malet-Martino M, Martino R. Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine. Drug Met. Disp. 30(11) 1221-9 (2002). (Pubitemid 35265829)
92. Wade K, Wilson I, Troke J, Nicholson J 19F and 1H magnetic resonance strategies for metabolic studies on fluorinated xenobiotics: application to flurbiprofen. J. Pharm. Biomed. Anal. 8(5) 401-10 (1990).
93. Dalvit C, Mongelli N, Papeo G et al. Sensitivity improvements in 19F NMR based screening experiments: theoretical considerations and experimental applications. J. Am. Chem. Soc. 127(38), 13380-5 (2005). (Pubitemid 41377634)
94. Bayer E, Albert K, Nieder M, Grom E. On-line coupling of High-Performance Liquid Chromatography and Nuclear Magnetic Resonance. J. Chromatogr. A 186, 497-507 (1979).
95. Corcoran O, Spraul M. LC-NMR-MS in drug discovery. Drug Discov Today 8(14), 624-31 (2003). (Pubitemid 36809257)
96. Sandvoss M, Bardsley B, Beck TL et al. HPLC-SPE-NMR in pharmaceutical development: capabilities and applications. Magn. Reson. Chem. 43, 762-770 (2005). (Pubitemid 41133758)
97. Wilson SR, Malerød H, Petersen D, Rise F, Lundanes E, Greibrokk T. An alternative multiple-trapping LC-SPE-NMR system. J. Sep. Sci. 30, 322-328 (2007). (Pubitemid 46359131)
98. Kammerer B, Sceible H, Zurek G et al. In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR-MS. Xenobiotica 37(3), 280-97 (2007). (Pubitemid 46439673)
99. Barfield M, Spooner N, Lad R, Parry S, Fowles S. Application of dried blood spots combined with HPLC-MS/MS for the quantification of acetaminophen in toxicokinetics studies. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 870, 32-37 (2008).
100. Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalysis method. Anal. Chem. 81, 1557-1563 (2009).
101. Edwards JL, Edwards RL, Reid KR, Kennedy RT. Effect of decreasing column diameter and use of off-line two dimensional chromatography on metabolite detection in complex mixtures. J. Chromatogr. A 1172, 127-134 (2007). (Pubitemid 350029810)
102. Schmidt A, Karas M, Dulcks T. Effect of different solution flow rates on analyte ion signals in nano-ESI MS, or: when does ESI turn into nano-ESI? J. Am. Soc. Mass Spectrom. 14, 492-500 (2003). (Pubitemid 36871630)
103. Dear GJ, Ayrton J, Plumb R, Fraser IJ. The rapid identification of drug metabolites using capillary liquid chromatography coupled to an ion trap mass spectrometer. Rapid Commun. Mass Spectrom. 13, 456-463 (1999). (Pubitemid 29150575)
104. Bajrami B, Zhao L, Schenkman JB, Rusling JF. Rapid LC-MS drug metabolite profling using microsomal enzyme bioreactors in a parallel processing format. Anal. Chem. 81, 9921-9929 (2009).
105. Ding J, Sorensen CM, Zhang Q et al. Capillary LC coupled with high-mass measurement accuracy mass spectrometry for metabolic profling. Anal. Chem. 79, 6081-6093 (2007). (Pubitemid 47282317)
106. Yu LJ, Chen Y, DeNinno MP, O'Connell TN, Hop CE. Identifcation of a novel glutathione adduct of diclofenac, 4'-hydroxy-2'-glutathione-deschloro- diclofenac, upon incubation with human liver microsomes. Drug Met. Dispos. 33, 484-488 (2005). (Pubitemid 40393189)
107. Staack RF, Varesio E, Hopfgartner G. The combination of liquid chromatography-tandem mass spectrometry and chip-based infusion for improved screening and characterisation of drug metabolites. Rapid Commun. Mass Spectrom. 19, 618-626 (2005). (Pubitemid 40332757)
108. Trunzer M, Graf D, Kiffe M. Comparison of a two-dimensional liquid chromatography-mass spectrometry approach with a chip-based nanoelectrospray device for structural elucidation of metabolites in human ADME study using a quadrupole time-of-fight mass spectrometer. Rapid Commun. Mass Spectrom. 21, 937-944 (2007). (Pubitemid 46426813)
109. Ma B, Zhang G, Qin J, Lin B. Characterization of drug metabolites and cytotoxicity assay simultaneously using an integrated microfuidic device. Lab Chip 9, 232-238 (2009).
110. Odijk M, Baumann A, Lohmann W et al. A microfuidic chip for electrochemical conversions in drug metabolism studies. Lab Chip 9, 1687-1693 (2009)
111. The Trizaic uPLC System with Nanotile Technology Waters Product Solution Note 720002641EN (May 2009).
112. Abu-Rabie P, Spooner N. Direct quantitative bioana lysis of drugs in dried blood spot samples using a thin-layer chromatography-mass spectrometer interface. Anal. Chem. 81, 10275-10284 (2009).
113. Takats Z, Wiseman JM, Gologan B, Cooks RG. Mass spectrometry sampling under ambient conditions with desorption electrospray ionisation. Science 306, 471-473 (2004). (Pubitemid 39372443)
114. Cody RB, Laramee JA, Durst HD. Versatile new ion source for the ana lysis of materials in open air under ambient conditions. Anal. Chem. 77, 2297-2302 (2005). (Pubitemid 40562727)
115. Twohig M, Shockcor JP, Wilson ID, Nicholson JK, Plumb RS. Use of an atmospheric solids ana lysis probe (ASAP) for high throughput screening of biological fuids: preliminary applications on urine and bile. J. Proteome Res. 9(7), 3590-3597 (2010).
116. Ardenkjaer-Larsen JH, Fridlund B, Gram A et al. Increase in signal-to-noise ratio <10,000 times in liquid-state NMR. Proc. Natl Acad. Sci. 100, 10158-10163 (2003). (Pubitemid 37071849)
117. 1H hyperpolarisation studies. Magn. Reson. Chem. 46, 713-717 (2008).
118. Lerche MH, Meier S, Jensen PR et al. Quantitative dynamic nuclear polarization-NMR on blood plasma for assay of drug metabolism. NMR Biomed. DOI: 10.1002/nbm.1561 (Epub ahead of print) (2010).
119. Adams RW, Aguilar JA, Atkinson KD et al. Reversible interactions with para-hydrogen enhance NMR sensitivity by polarization transfer. Science 323, 1708-1711 (2009).
120. Creaser CS, Griffths JR, Bramwell CJ, Noreen S, Hill CA, Paul Thomas CL. Ion mobility spectrometry: a review. Part 1. Structural ana lysis by mobility measurement. Analyst 129, 984-994 (2004). (Pubitemid 39539238)
121. Williams JP, Bugarcic T, Habtemariam A et al. Isomer separation and gas-phase confgurations of organoruthenium anticancer complexes: Ion Mobility Mass Spectrometry and Modelling. J. Am. Soc. Mass Spectrom. 20, 1119-1122 (2009).
122. Dear GJ, Munoz-Muriedas J, Beaumont C et al. Sites of metabolic substitution: investigating metabolite structures utilising ion mobility and molecular modelling. Rapid Commun. Mass Spectrom. 24, 3157-3162 (2010).
123. Bateman K, Muenster H, Kellmann M, Tiller PR, Papp R, Taylor LC. Full scan data acquisition for rapid quantitative and qualitative ana lysis using a bench-top nonhybrid ESI-Orbitrap mass spectrometer. Presented at: the 56th ASMS Conference on Mass Spectrometry and Allied Topics. Denver, CO, USA, 1-5 June 2008.
124. Bateman KP, Kellmann M, Muenster H, Papp R, Taylor L. Quantitative-qualitative data acquisition using a benchtop Orbitrap mass spectrometer. J. Am. Soc. Mass Spectrom. 20(8), 1441-50 (2009).
125. Thite MA, Boughtfower R, Caldwell J et al. Ionisation in the absence of high voltage using supercritical fuid chromatography: a possible route to increased signal. Rapid Commun. Mass Spectrom. 22, 3673-3682 (2008).
126. Karanam BV, Welch CJ, Reddy VG, Chilenski J, Biba M, Vincent S. Species differential stereoselective oxidation of a methylsulfde metabolite of MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl) methyl]-2-meth oxy-N-[[(4-trifuoromethyl) phenyl]methyl]benzamide], a peroxisome proliferator-activated receptor dual agonist. Drug Metab. Dispos. 32(10), 1061-8 (2004). (Pubitemid 39287578)
127. Cheng H, Schwartz MS, Vickers S et al. Metabolic disposition of simvastatin in patients with t-tube drainage. Drug Met. Dispos. 22, 139-142 (1994). (Pubitemid 24045393)
128. Balani SK, Xu X, Pratha V et al. Metabolic profles of montelukast sodium (singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 25(11), 1282-7 (1997). (Pubitemid 27490673)
129. Lundahl A, Lennernas H, Knutson L, Bondesson U, Hedeland M. Identifcation of fnasteride metabolites in human bile and urine by high-performance liquid chromatography-tandem mass spectrometry. Drug Met. Dispos. 37, 2008-2017 (2009).
130. Guiney WJ, Beaumont C, Thomas SR. Use of the Entero-Test®, a novel approach for the noninvasive capture of biliary metabolites in dogs. Drug Met.Dispos. 38, 851-856 (2010).
131. Guiney WJ, Beaumont C, Thomas SR et al. Use of the Entero-Test®, a simple approach for the non-invasive capture and qualitative characterization of biliary metabolites in man. J. Clin Pharmacol. (In Press)